Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Journal of Applied Pharmaceutical Research
Chauhan, Ashish Singh
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : journal of applied pharmaceutical research

 1 
Pharmacophore insights and molecular docking of ciprofloxacin analogues against 2XE1: strategies for reduced antibiotic resistance Katlaria, Sanjana; Chauhan, Ashish Singh; Kumar, Krishna; Kumar, Mohit; Chauhan, Bhumika; Jakhmola, Vikash
Journal of Applied Pharmaceutical Research Vol. 12 No. 6 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i6.660

Abstract

Background: Antibiotic resistance is a silent pandemic disease that is growing and causing a global threat. Existing antibiotics are less effective against infectious diseases, so we must discover more potent and effective drugs. The latest report from the World Health Organization (WHO) underscores the global nature of the situation, revealing that high levels of antibiotic resistance in bacteria worldwide lead to life-threatening bloodstream infections and resistance to treatment. Methods: This study focuses on the Molecular Docking and Pharmacophore Modeling of Ciprofloxacin and its analogs to explore ligand-protein interactions and identify potent drugs against AMR. Twenty ciprofloxacin analogs, designed using ChemDraw Pro12.0, were docked with the 2XE1 protein. Molecular docking assessed the binding affinity, with Arguslab 4.0 scoring the lowest docking scores to indicate strong interactions and biological activity. Pharmacophore modeling identified essential molecular features like HBA, HBD, and AI for optimal biological activity. Results: The computational screening identified several compounds with improved binding properties, showing greater affinity towards ALA129, TYR149, and PHE88 amino acids, essential for biological activity. Conclusion: The study identifies the best analog of ciprofloxacin, which can effectively combat antibiotic resistance. Compound 13 showed promising docking scores and relevant pharmacophoric features, outperforming the parent ciprofloxacin in binding affinity, suggesting it could be a potent drug candidate against AMR.
Nanostructured lipid carriers (NLCs): A comprehensive review of drug delivery advancements Panwar, Pramesh; Kumar, Saurabh; Chand, Pallavi; Chauhan, Ashish Singh; Jakhmola, Vikash
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.676

Abstract

Background: Nano-structured lipid carriers (NLCs) have emerged as a significant advancement in lipid-based drug delivery systems. Compared to Solid Lipid Nanoparticles (SLNs), NLCs offer improved drug loading capacity, stability, and controlled release profiles. Objective: This review article explores the structural and functional benefits of NLCs, their enhanced bioavailability, and their potential in targeted therapeutic agent delivery. Methodology: We investigated the unique combination of solid and liquid lipids in NLCs, which creates an internal structure for improved drug encapsulation and sustained release. Various methods were analyzed for their contribution to NLC efficacy, including high-pressure homogenization and solvent emulsification. Results and Discussion: NLCs demonstrated encapsulation efficiency ranging from 85–95%, with particle sizes between 100–300 nm. Drug release was sustained over 24 hours, affirming their effectiveness in controlled drug delivery. Applications of NLCs were highlighted across diverse delivery modes, including topical, pulmonary, oral, parenteral, and ocular. Challenges such as scaling production, overcoming biological barriers, and ensuring regulatory compliance were also addressed. Conclusion: NLCs present a promising future in pharmaceutical sciences, with the potential to improve therapeutic outcomes in complex diseases like cancer and neurodegenerative disorders. Continued research into NLC formulations is critical for advancing patient outcomes and addressing global health challenges.
Co-Authors Chand, Pallavi Chauhan, Bhumika Jakhmola, Vikash Katlaria, Sanjana Kumar, Krishna Kumar, Mohit Kumar, Saurabh Panwar, Pramesh